Ecto-F1-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins

- Ecto-F1-ATPase is coupled to P2Y ADP-receptors and modulates HDL functions.
- On hepatocytes, ecto-F1-ATPase/P2Y13 pathway contributes to holo-HDL endocytosis.
- On endothelial cells, ecto-F1-ATPase promotes cell survival and HDL transcytosis.
- Serum F1-ATPase inhibitor (IF1) is an independent determinant of HDL-C and CHD risk.
- Therapeutic strategies targeting F1-ATPase/P2Y13 pathway are explored.

The atheroprotective property of High Density Lipoprotein (HDL) is supported by many epidemiological studies and cellular and in vivo approaches on animal models. While the anti-atherogenic effects of HDL are thought to derive primarily from its role in reverse cholesterol transport, together with anti-inflammatory, anti-oxidant, anti-thrombotic and cytoprotective properties, the mechanisms that support these effects are still not completely understood. However, many advances in identifying the cellular partners involved in HDL functions have been made over the last two decades. This review highlights the diverse roles of the HDL receptor ecto-F1-ATPase coupled to purinergic P2Y receptors in the modulation of important metabolic and vascular functions of HDL. On hepatocytes, the ecto-F1-ATPase is coupled to P2Y13 receptor and contributes to HDL holoparticle endocytosis. On endothelial cells, ecto-F1-ATPase/P2Ys pathway is involved in HDL-mediated endothelial protection and HDL transcytosis. The clinical relevance of this F1-ATPase/P2Ys axis in humans has recently been supported by the identification of serum F1-ATPase inhibitor (IF1) as an independent determinant of HDL-Cholesterol (HDL-C) and coronary heart disease risk. Therapeutic strategies targeting F1-ATPase/P2Y pathways for the treatment of atherosclerosis are currently being explored.